Exposure science is now being used for the early diagnosis of anthrax and to assess the efficacy of medical countermeasures. Detection and quantification of deadly anthrax toxins are used to identify exposure to Bacillus anthracis spores and the development of clinical anthrax at very early stages of disease. In rabbits and nonhuman primates, anthrax lethal factor can be detected in serum or plasma 12 hours after inhalation exposure to B. anthracis spores, which provides much earlier diagnosis than is possible with traditional biochemical techniques. Data from human clinical and animal studies have indicated that anthrax lethal factor levels in serum and plasma are predictive of the severity of disease and effectiveness of treatment. Thus, monitoring anthrax toxin levels is a crucial tool that enables earlier medical treatments and guide both the course of treatments and the development of new medical countermeasures. In the case of an anthrax attack by terrorists, such rapid identification would be invaluable in saving lives by enabling treatment of immediate contacts and preventing the spread of this highly infectious agent.
We now have the technology to detect and quantify anthrax toxin levels. This technology has tremendous promise for diagnosis at very early stages of disease and monitoring the efficacy of treatments, including those for disease arising from anthrax-related terrorist events. 
BACKGROUND
Exposure to the spores of Bacillus anthracis causes the disease anthrax. Spores gain entry into the host through dermal abrasions, gastrointestinal lesions, injection (usually in intravenous drug use), and inhalation, which cause cutaneous, gastrointestinal, injection, and inhalation anthrax, respectively. Anthrax is a naturally occurring disease in many parts of the world, and it remains a bioterrorism threat. Inhalation anthrax has a mortality rate higher than 90% if untreated and is often deadly even with antibiotic therapy. During the anthrax-letter attacks of 2001, mortality was 45%, even with antibiotics and aggressive supportive care (Jernigan et al., 2002) . Additionally, there is a "point of no return" during anthrax infection after which all traditional treatments may fail.
The lethal consequences of this disease are caused by the anthrax toxins. "Lethal toxin" inactivates cell components central to the victims' defense against infection. "Edema toxin" causes massive fluid retention and swelling (edema), as well as depressing some parts of immune defenses. Both of these toxins also cause bleeding late in the course of infection.
IMPACT AND IMPLICATIONS FOR EXPOSURE SCIENCE
Diagnosis of anthrax in the early stages of disease is critical for effective treatment and thus to saving lives. Mass spectrometric detection and quantification of anthrax toxins are highly selective and rapid diagnostic tools for early disease. The ability to quantify the toxins provides an additional benefit in understanding the course of disease and the efficacy of treatments and therapies. For the anthrax toxins to be detected early in the disease, they must be quantified at exquisitely low levels. Exposure science techniques have been developed to achieve this (Boyer et al., 2007) .
Detection and quantification of the anthrax toxin lethal factor represent a major advancement in the diagnosis of anthrax. The anthrax exposure science technology has the following important features:
Detects infection earlier. Monitoring lethal factor detects B. anthracis infection as early as 12 hours after exposure to anthrax spores and as much as 24 hours earlier than other technologies (Boyer et al., 2009) . Anthrax can be detected even before symptoms such as fever are present.
Shorter time to the first result. Quantitative lethal factor measurements and analyses are completed within 4 hours. By comparison, traditional biochemical approaches to diagnosis anthrax may take several days to produce definitive results.
Analyzes many more samples per day. The new method to measure lethal factor has been automated and can analyze hundreds to thousands of samples per day. This throughput represents a significant advancement over previous techniques. Not subject to antibiotic interference. Quantitative lethal factor monitoring can be used to identify and track infection even if antibiotic treatment has started, unlike with historical methods, which cannot consistently detect infection in people undergoing treatment.
Quantifies toxin to track course of infection and responses to treatment. Quantification of lethal factor is an excellent measure of treatment effectiveness by tracking changes in toxin levels. This capability could be helpful in the clinical management of patients who are not progressing well. For example, such information could help doctors determine whether additional or alternative therapeutics are necessary.
Monitoring anthrax lethal factor levels in animal and clinical studies has already yielded insights into the course of infection and responses to treatment. The animal study data show that the progression of infection can occur in three stages, during which traditional diagnostic tests can be at first positive but then transiently revert to negative, only to become positive again later in infection. In contrast to these traditional tests, quantification of anthrax lethal factor is detected throughout all stages of infection (Boyer et al., 2009 ). In addition, the animal studies have shown that lethal factor levels may be predictive of the stage or severity of illness, and they have been used to establish a potential toxin-related point of no return, when mortality is very likely. This would indicate that additional therapeutics are required to remove high toxin levels from the blood. Quantification of lethal factor levels on a daily basis during a clinical case would allow physicians to monitor changes and adjust treatment accordingly.
The application of exposure science to detect and quantify anthrax lethal factor levels has recently been used to respond to clinical cases of inhalation (Walsh et al., 2007) , cutaneous, injection, and gastrointestinal anthrax. A great deal has been learned about the course of B. anthracis infection in humans and the efficacy of treatments. The information gained can be used to evaluate therapeutics and help guide medical intervention. The use of exposure science to detect and quantify toxins produced by human pathogens can have a major impact on the diagnosis and treatment of an even wider range of infectious diseases.
